LIPH generates 2-acyl lysophosphatidic acid (lysoPA as well as LPA) which is a ligand for the LPA6 receptor, a receptor that is related to the P2Y family of receptors
Our GLP-1 Weight Loss Program in Austin is a favorite among Austin residents seeking weight management solutions
10.1007/s13555-018-0278-6 2 AlonsoL.FuchsE
Reducing the most harmful drinking patterns could make a meaningful difference for patients. In a linked commentary, also published in The Lancet, academics from the US said: The importance of evaluating GLP-1 therapies as new therapeutic options for alcohol use disorder cannot be overstated, Should forthcoming studies confirm efficacy of GLP-1 therapies for alcohol use disorder across a broad range of populations and settings, public health implications could be substantial a possibility that deserves celebration. Commenting on the study, Dr Marie Spreckley, research programme manager at the University of Cambridge, said: Overall, this study provides encouraging early evidence for a potential new treatment approach for people with co-occurring obesity and alcohol use disorder, but larger and longer-term trials in more diverse populations are needed before this can inform routine clinical practice. Matt Field, professor of psychology at the University of Sheffield, said: This well-conducted trial showed that 26 weeks of semaglutide treatment led to a marked reduction in the frequency of heavy drinking among people with alcohol use disorder who were also obese
In first-episode psychosis, Schwarz et al
The University of Utah Drug Information Service compiles drug shortage statistics, which are mostly low-cost, generic drugs and often sterile injectables
